Figure 1. Systemic levels of NO 2 -CLA metabolites are lower in SCD patients. (A-B) Total NO 2 -CLA and DH-NO 2 -CLA levels (esterified plus free acid fraction) in healthy (n = 12) and SCD (n = 9) plasma extracts. (C) Representative urine LC-MS/MS chromatograms showing total (top) and isomer-spe... More about this image found in Systemic levels of NO 2 -CLA metabolites are lower in SCD patients. (A-B) ...

Figure 2. NO 2 -OA protects against hemin-induced renal injury in SCD. (A-B) Nrf2-dependent gene expression in HK2 cells treated with NO 2 -CLA and NO 2 -OA (n = 3). ∗ P < .05, ∗∗ P < .001, ∗∗∗ P < .0001 by 1-way ANOVA and Dunnett posttest. (C) Protein expression 16 hours after NO 2 ... More about this image found in NO 2 -OA protects against hemin-induced renal injury in SCD. (A-B) Nrf2-de...

Figure 1. Network diagram. More about this image found in Network diagram.

Figure 2. NMA results for response using COVID-19–adjusted data from ALPINE trial. ORs and Prob better for zanubrutinib vs comparators in high-risk patients. More about this image found in NMA results for response using COVID-19–adjusted data from ALPINE trial. O...

Figure 3. NMA results for PFS-INV using COVID-19–adjusted data from ALPINE trial. HRs and Prob better for zanubrutinib vs comparators. More about this image found in NMA results for PFS-INV using COVID-19–adjusted data from ALPINE trial. HR...

Figure 1. Study design. Design of the phase 1/2 open-label, single ascending dose–finding 101HEMB01 study of DTX101, and the noninterventional follow-up 101HEMB02 study. More about this image found in Study design. Design of the phase 1/2 open-label, single ascending dose–fi...

Figure 2. Individual patient outcomes. (A-F) Individualized patient outcomes including the timing of FIX replacement therapy (blue marker), steroid administration (red square), FIX levels (orange square/line), and ALT levels (green circle/line). More about this image found in Individual patient outcomes. (A-F) Individualized patient outcomes includi...

Figure 3. Measures of liver enzymes (ALT/AST). Mean ALT and AST levels across the 101HEMB01 (A-B) and 101HEMB02 (C-D) studies. Gray markers indicate cohort 1 (DTX101; 1.6 × 10 12 genome copies/kg), and orange markers indicate cohort 2 (DTX101; 5.0 × 10 12 genome copies/kg). More about this image found in Measures of liver enzymes (ALT/AST). Mean ALT and AST levels across the 10...

Figure 1. Study overview. (A-B) Potential models for circulatory clearance of donor RBCs as a function of cell deformability. If circulatory clearance is independent of deformability, then the deformability distribution of circulating cells remains unchanged (A). If circulatory clearance is depe... More about this image found in Study overview. (A-B) Potential models for circulatory clearance of donor ...

Figure 2. AMT treatment reduces murine RBC deformability. Deformability distributions of control and AMT-treated mouse RBCs. Data are shown for 2 pooled donor groups with n = 3 and n = 4, respectively. Ctrl, control. More about this image found in AMT treatment reduces murine RBC deformability. Deformability distribution...